New Evidence that Circumcision Might Protect MSM from HIV

Sten Vermund,Han-zhu Qian,Yuhua Ruan,Yiming Shao,Yu Liu,Douglas Milam,Hans Spiegel,Dongliang Li,Lu Yin

DOI: https://doi.org/10.1097/01.qai.0000456053.93927.60

2014-01-01

Journal of Acquired Immune Deficiency Syndromes

Abstract:Objective: To study the association of male circumcision and odds of HIV and syphilis among Chinese men who have sex with men (MSM). Design: Cross-sectional study. Methods: MSM were recruited from the community and HIV clinics in Beijing, China. Circumcision status was evaluated by genital examination and self-report; and anal sexual role was assessed by questionnaire interview. Associations of circumcision status with HIV and syphilis infections were assessed through multivariate logistic regression analysis. Results: Among 1155 participants including 242 with known seropositive and 913 with unknown HIV status at enrollment, the circumcision rate by self-report (10.4%) was higher than by genital exam (8.2%; P < 0.01). Compared to uncircumcised men who practiced predominantly receptive or versatile anal sex, the adjusted risk of HIV among uncircumcised men practicing predominantly insertive anal sex was lower by 57% (adjusted odds ratio [aOR], 0.43; 95% confidence interval CI: 0.32 to 0.59). Among circumcised men practicing predominantly receptive or versatile anal sex, it was lower by 52% (aOR, 0.48; 95% CI: 0.22 to 1.02), and among circumcised men practicing predominantly insertive anal sex was lower by 85% (aOR, 0.16; 95% CI: 0.04 to 0.65). After adjusting for demographic covariates and anal sex role, male circumcision was associated with a 54% lower odds of being HIV seropositive (aOR, 0.46; 95% CI: 0.24 to 0.89).Circumcision was not significantly associated with syphilis protection (aOR, 0.79; 95% CI: 0.45 to 1.42). Conclusions: Circumcised MSM were less likely to have acquired HIV, especially among men practicing predominantly insertive anal intercourse. It is suggested that circumcision may be a viable global HIV prevention strategy for MSM, but a clinical trial will be needed. The HPTN 079 trial is a preparatory study to assess the feasibility of such a trial in a variety of global setting. We expect the HPTN 079 protocol to begin in 7 global and US field sites in early 2015.